Edwards Lifesciences Total decreased by 5.3% to $1.23B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 48.9%, from $827.80M to $1.23B. Over 5 years (FY 2020 to FY 2025), Total shows an upward trend with a 7.1% CAGR.
Changes reflect the scale of the investment portfolio and the firm's capital deployment strategy into debt instruments.
This represents the original cost of debt securities classified as available-for-sale, adjusted for amortization of prem...
Standard metric for financial institutions and insurance companies holding fixed-income portfolios.
other_available_for_sale_debt_securities_amortized_cost_basis| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.14B | $1.40B | $2.19B | $1.89B | $1.71B | $1.72B | $1.55B | $1.36B | $1.23B | $1.06B | $926.10M | $767.70M | $534.30M | $900.90M | $1.03B | $827.80M | $839.40M | $1.18B | $1.30B | $1.23B |
| QoQ Change | — | +22.9% | +56.5% | -13.9% | -9.4% | +0.4% | -9.8% | -11.9% | -9.6% | -14.1% | -12.6% | -17.1% | -30.4% | +68.6% | +13.9% | -19.3% | +1.4% | +40.4% | +10.5% | -5.3% |
| YoY Change | — | — | — | — | +50.1% | +22.7% | -29.4% | -27.7% | -27.9% | -38.3% | -40.2% | -43.7% | -56.7% | -14.9% | +10.8% | +7.8% | +57.1% | +30.8% | +26.8% | +48.9% |